79. Exploring the Antibiotic Pipeline 2018
Thursday, October 4, 2018: 2:00 PM-3:15 PM
Room: N Hall D

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • review novel antibiotics in the pipeline including mechanism of action and clinical applications
  • discuss the possible niche of novel therapies against antibiotic-resistant organisms
  • evaluate clinical and price-clinic data of new antimicrobial molecules that are being developed.

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Researchers, Scientists

Tracks: Trainee, Global ID, Investigative ID, Pediatric ID, Adult ID

Moderators:  David R. Andes, M.D., FIDSA, University of Wisconsin , Cesar Arias, MD, PhD, FIDSA, University of Texas Health Science Center at Houston , Robert Bonomo, MD, Louis Stokes Cleveland VA Medical Center and John Mohr, PharmD, Medical Affairs Strategic Solution, LLC

2:00 PM
2:15 PM
2:30 PM
2:45 PM
SCY-078 - SCYNEXIS, Inc.
David Angulo, MD

CME Credits: No CME credit is offered for this session.

ACPE Number: 0221-9999-18-208-L04-P


D. R. Andes, None

C. Arias, Merck & Co., Inc.: Grant Investigator , Research support . MeMed: Grant Investigator , Research support . Allergan: Grant Investigator , Research support .

R. Bonomo, None

J. Mohr, scPharmaceuticals: Employee and Shareholder , Salary .

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.